Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEPTON: Oral Regimens for Chronic HCV
NCT02202980Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Aug 2014
- Primary completion
- Mar 2016
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of voxilaprevir in hepatitis C virus infection (15 arms), sponsored by Gilead Sciences. Primary endpoints: Sustained Virologic Response 12 Weeks After Discontinuation of Therapy and Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event up to 24 weeks. Started Aug 2014; status: completed.
02
Drugs
voxilaprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT02202980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02202980.